


## Unoprostone

Cat. No.:	HY-106916
CAS No.:	120373-36-6
Molecular Formula:	C <sub>22</sub> H <sub>38</sub> O <sub>5</sub>
Molecular Weight:	382.53
Target:	Potassium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Unoprostone, a prostaglandin F <sub>2α</sub> analogs (PGAs), activates BK channels to reduce oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction. Unoprostone reduces intraocular pressure and is used topically for glaucoma or ocular hypertension <sup>[1]</sup> .								
<b>In Vitro</b>	<p>Pretreatment with Unoprostone (0.01, 0.1, 1 μM; 1 h before H<sub>2</sub>O<sub>2</sub> treatment) protects against H<sub>2</sub>O<sub>2</sub>-induced cell death in a concentration-dependent manner and the effect is significant at 0.1 μM and 1 μM concentrations<sup>[1]</sup>.</p> <p>Pretreatment with Unoprostone at concentrations of 0.1 to 3 μM protects against light-induced cell death in a concentration-dependent manner; the effect is significant at the 1 and 3 μM concentrations. Unoprostone reduces the morphological change, and it significantly inhibits the low mitochondrial membrane potential and cell death induced by light irradiation<sup>[1]</sup>.</p> <p>Unoprostone has prostaglandin F<sub>2α</sub> receptors (FP) binding affinity with a K<sub>i</sub> of 3.86 μM<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>H<sub>2</sub>O<sub>2</sub>-induced photoreceptor cell</td> </tr> <tr> <td>Concentration:</td> <td>0.01, 0.1, 1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>1 hour before H<sub>2</sub>O<sub>2</sub> treatment</td> </tr> <tr> <td>Result:</td> <td>Protected against H<sub>2</sub>O<sub>2</sub>-induced cell death in a concentration-dependent manner.</td> </tr> </table>	Cell Line:	H <sub>2</sub> O <sub>2</sub> -induced photoreceptor cell	Concentration:	0.01, 0.1, 1 μM	Incubation Time:	1 hour before H <sub>2</sub> O <sub>2</sub> treatment	Result:	Protected against H <sub>2</sub> O <sub>2</sub> -induced cell death in a concentration-dependent manner.
Cell Line:	H <sub>2</sub> O <sub>2</sub> -induced photoreceptor cell								
Concentration:	0.01, 0.1, 1 μM								
Incubation Time:	1 hour before H <sub>2</sub> O <sub>2</sub> treatment								
Result:	Protected against H <sub>2</sub> O <sub>2</sub> -induced cell death in a concentration-dependent manner.								
<b>In Vivo</b>	<p>Unoprostone (0.06%, 0.12%; topical instillation; 3 μl) reduces mouse intraocular pressure (IOP) in a dose-dependent manner<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male mice (6 weeks old)<sup>[3]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.06%, 0.12%</td> </tr> <tr> <td>Administration:</td> <td>Topical instillation; 3 μl</td> </tr> <tr> <td>Result:</td> <td>Reduced mouse IOP in a dose-dependent manner.</td> </tr> </table>	Animal Model:	Male mice (6 weeks old) <sup>[3]</sup>	Dosage:	0.06%, 0.12%	Administration:	Topical instillation; 3 μl	Result:	Reduced mouse IOP in a dose-dependent manner.
Animal Model:	Male mice (6 weeks old) <sup>[3]</sup>								
Dosage:	0.06%, 0.12%								
Administration:	Topical instillation; 3 μl								
Result:	Reduced mouse IOP in a dose-dependent manner.								

---

## REFERENCES

---

- [1]. Tsuruma K, et al. Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction, by activating BK channels. *Mol Vis*. 2011;17:3556-65. Epub 2011 Dec 30.
- [2]. Kelly CR, et al. Real-time intracellular Ca<sup>2+</sup> mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. *J Pharmacol Exp Ther*. 2003 Jan;304(1):238-45.
- [3]. Ota T, et al. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. *Invest Ophthalmol Vis Sci*. 2005 Nov;46(11):4159-63.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA